CJC-1293
A GHRH(1-29) analogue from the same development line as CJC-1295. WADA names it, doping laboratories test for it, and no study found gave it to people.
CJC-1293 is a synthetic analogue of the first 29 residues of growth hormone-releasing hormone. PubChem's record (CID 139593405) gives a 30-residue amide with a maleimidopropionyl group on the C-terminal lysine, while a 2023 analytical paper describes the CJC-1293 it tested as differing from sermorelin only in the chirality of one amino acid. The papers found are anti-doping methods that detect it in plasma and urine. WADA names it among prohibited GHRH analogues. It was never approved, and no study found gave it to people.
No dosing data yet Details ↓
Recommended Dosing
No dosing data yet
This page has no dosing data yet.
Mechanism of action
A GHRH analogue, a class that stimulates growth hormone release through the GHRH receptor; no study found measured CJC-1293's own activity.
Primary uses
- Anti-doping: detection methods
Typical dosing
No human dose: no study found gave CJC-1293 to people; the papers read are analytical.
Regulatory status
Never approved: Drugs@FDA and the EMA medicines list hold no record (searched October 28, 2026). Named on the WADA 2026 and 2027 Prohibited Lists under S2.2.4 (GHRH and its analogues).
Status as of this entry's last review, October 28, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.
What we checked
CJC-1293 is a GHRH analogue known from anti-doping chemistry; this section records what can be checked.
Identity, computed
| Structure | a GHRH(1-29) analogue amide with a maleimidopropionyl-modified C-terminal lysine (PubChem CID 139593405, synonym CJC-1293) |
| Formula | C162H263N47O46S (PubChem) |
| Molecular weight | 3637.2 g/mol (PubChem) |
| Other description | differs from sermorelin by the chirality of one amino acid (2023 analytical paper) |
The two sources describe different forms, so no sequence is computed here; the formula and weight are PubChem's for the maleimidopropionyl form.
Regulatory status, read October 28, 2026
Drugs@FDA: 0 records for “CJC-1293”. EMA medicines list: 0 records for “CJC-1293”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 80 trials), so a zero here is an absence, not a broken search. WADA 2026: section S2.2.4; WADA 2027: section S2.2.4.
What the studies show
A 2015 initial-testing method for peptides over 2 kDa covers sermorelin, CJC-1293, CJC-1295 and tesamorelin (Thomas et al., 2015); a 2016 plasma method detects the same four and a CJC-1293 metabolite (Knoop et al., 2016).
A 2023 capillary electrophoresis method separated sermorelin and CJC-1293, described as differing in the chirality of one amino acid (Otin et al., 2023).
What we looked for and did not find
No study giving it to people or animals for an effect, no registry record and no drug approval.
| Source | Query | Results, October 28, 2026 | What it was |
|---|---|---|---|
| PubMed | "CJC-1293"[tiab] OR "CJC 1293"[tiab] | 3 | anti-doping methods |
| ClinicalTrials.gov | CJC-1293 | 0 | |
| Drugs@FDA (openFDA) | CJC-1293 | 0 | |
| EMA medicines list | CJC-1293 | 0 |
References
- [other] PubChem CID 139593405, CJC-1293 (UNII ZZM61DP6TS): formula C162H263N47O46S, molecular weight 3637.2. Read October 28, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/139593405
- [pubmed] Knoop A, et al. "Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS." Anal Bioanal Chem, 2016;408(12):3145-53. PMID: 26879649.
- [pubmed] Thomas A, et al. "Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS." Drug Test Anal, 2015;7(11-12):990-8. PMID: 26382721.
- [pubmed] Otin J, et al. "Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis." Electrophoresis, 2023;44(9-10):807-817. PMID: 36787346.
Related peptides
Guides & tools
Explore with tools
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.